PATHFAST™ NTproBNP is an immunoassay for the in vitro quantitative determination of N-terminal pro-B-type natriuretic peptide (NTproBNP) in anticoagulated whole blood and plasma on the PATHFAST™ analyzer. PATHFASTTM NTproBNP can be used as an aid in the diagnosis in patients suspicious for congestive heart failure, the detection left ventricular dysfunction of and in the assessment of the severity of congestive heart failure (CHF). PATHFAST™ NTproBNP can also be used in the risk stratification in patients with acute coronary syndromes (ACS) and congestive heart failure and for monitoring the therapy in patients with left ventricular dysfunction. NTproBNP allows rule out of heart failure due to consistent and very high negative predictive values and has also proven as a prognostic marker in severe sepsis and septic shock. In patients with stable coronary artery disease NTproBNP is strongly associated with the cardiovascular outcome. NTproBNP is valuable in the identification and exclusion of acute heart failure of dyspneic patients presenting in the emrgency department. NTproBNP is also related to the long-term outcome presenting in the emergency department with and without cardiovascular impairment. NTproBNP also identifies subjects with rheumatoid disease who are at risk for cardiovascular morbidity and mortality. Stdudies have shown that NTproBNP is useful as a simple non-invasive method of screening patients with arthritis before starting or continuing therapy with non steroidal anti-inflammatory drugs (NSAIDs).